nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—MAOA—attention deficit hyperactivity disorder	0.224	0.276	CbGaD
Phenylpropanolamine—DRD1—attention deficit hyperactivity disorder	0.204	0.251	CbGaD
Phenylpropanolamine—SLC6A3—attention deficit hyperactivity disorder	0.193	0.238	CbGaD
Phenylpropanolamine—ADRA2A—attention deficit hyperactivity disorder	0.19	0.234	CbGaD
Phenylpropanolamine—SLC6A2—locus ceruleus—attention deficit hyperactivity disorder	0.00861	0.176	CbGeAlD
Phenylpropanolamine—MAOA—locus ceruleus—attention deficit hyperactivity disorder	0.00793	0.162	CbGeAlD
Phenylpropanolamine—SLC6A2—autonomic nervous system—attention deficit hyperactivity disorder	0.00457	0.0936	CbGeAlD
Phenylpropanolamine—DRD1—forebrain—attention deficit hyperactivity disorder	0.00164	0.0336	CbGeAlD
Phenylpropanolamine—SLC6A3—forebrain—attention deficit hyperactivity disorder	0.00132	0.027	CbGeAlD
Phenylpropanolamine—ADRB1—forebrain—attention deficit hyperactivity disorder	0.00125	0.0256	CbGeAlD
Phenylpropanolamine—DRD1—midbrain—attention deficit hyperactivity disorder	0.00109	0.0222	CbGeAlD
Phenylpropanolamine—SLC6A2—forebrain—attention deficit hyperactivity disorder	0.00107	0.0218	CbGeAlD
Phenylpropanolamine—ADRB1—cardiovascular system—attention deficit hyperactivity disorder	0.00106	0.0217	CbGeAlD
Phenylpropanolamine—Levonordefrin—ADRA2C—attention deficit hyperactivity disorder	0.000994	0.16	CrCbGaD
Phenylpropanolamine—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.000991	0.0203	CbGeAlD
Phenylpropanolamine—MAOA—forebrain—attention deficit hyperactivity disorder	0.000982	0.0201	CbGeAlD
Phenylpropanolamine—DRD1—nervous system—attention deficit hyperactivity disorder	0.000892	0.0183	CbGeAlD
Phenylpropanolamine—SLC6A3—midbrain—attention deficit hyperactivity disorder	0.000872	0.0178	CbGeAlD
Phenylpropanolamine—DRD1—central nervous system—attention deficit hyperactivity disorder	0.000859	0.0176	CbGeAlD
Phenylpropanolamine—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.000838	0.0171	CbGeAlD
Phenylpropanolamine—MAOA—cardiovascular system—attention deficit hyperactivity disorder	0.00083	0.017	CbGeAlD
Phenylpropanolamine—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.000753	0.0154	CbGeAlD
Phenylpropanolamine—SLC6A3—nervous system—attention deficit hyperactivity disorder	0.000717	0.0147	CbGeAlD
Phenylpropanolamine—SLC6A3—central nervous system—attention deficit hyperactivity disorder	0.00069	0.0141	CbGeAlD
Phenylpropanolamine—DRD1—brain—attention deficit hyperactivity disorder	0.000682	0.014	CbGeAlD
Phenylpropanolamine—ADRB1—nervous system—attention deficit hyperactivity disorder	0.00068	0.0139	CbGeAlD
Phenylpropanolamine—SLC6A3—cerebellum—attention deficit hyperactivity disorder	0.000675	0.0138	CbGeAlD
Phenylpropanolamine—ADRB1—central nervous system—attention deficit hyperactivity disorder	0.000655	0.0134	CbGeAlD
Phenylpropanolamine—MAOA—midbrain—attention deficit hyperactivity disorder	0.000648	0.0133	CbGeAlD
Phenylpropanolamine—SLC6A2—nervous system—attention deficit hyperactivity disorder	0.000579	0.0118	CbGeAlD
Phenylpropanolamine—SLC6A2—central nervous system—attention deficit hyperactivity disorder	0.000557	0.0114	CbGeAlD
Phenylpropanolamine—SLC6A3—brain—attention deficit hyperactivity disorder	0.000548	0.0112	CbGeAlD
Phenylpropanolamine—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.000538	0.011	CbGeAlD
Phenylpropanolamine—MAOA—nervous system—attention deficit hyperactivity disorder	0.000533	0.0109	CbGeAlD
Phenylpropanolamine—ADRB1—brain—attention deficit hyperactivity disorder	0.00052	0.0106	CbGeAlD
Phenylpropanolamine—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000518	0.0106	CbGeAlD
Phenylpropanolamine—MAOA—central nervous system—attention deficit hyperactivity disorder	0.000513	0.0105	CbGeAlD
Phenylpropanolamine—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.000506	0.0104	CbGeAlD
Phenylpropanolamine—MAOA—cerebellum—attention deficit hyperactivity disorder	0.000502	0.0103	CbGeAlD
Phenylpropanolamine—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000497	0.0102	CbGeAlD
Phenylpropanolamine—Methamphetamine—ADRA2C—attention deficit hyperactivity disorder	0.000484	0.078	CrCbGaD
Phenylpropanolamine—SLC6A2—brain—attention deficit hyperactivity disorder	0.000442	0.00905	CbGeAlD
Phenylpropanolamine—Levonordefrin—ADRA2A—attention deficit hyperactivity disorder	0.000424	0.0683	CrCbGaD
Phenylpropanolamine—ADRA1A—brain—attention deficit hyperactivity disorder	0.000411	0.00841	CbGeAlD
Phenylpropanolamine—Tranylcypromine—MAOA—attention deficit hyperactivity disorder	0.000409	0.0659	CrCbGaD
Phenylpropanolamine—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.000409	0.00837	CbGeAlD
Phenylpropanolamine—MAOA—brain—attention deficit hyperactivity disorder	0.000407	0.00834	CbGeAlD
Phenylpropanolamine—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.000394	0.00806	CbGeAlD
Phenylpropanolamine—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000385	0.00787	CbGeAlD
Phenylpropanolamine—Phentermine—MAOA—attention deficit hyperactivity disorder	0.000343	0.0552	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—MAOA—attention deficit hyperactivity disorder	0.000325	0.0524	CrCbGaD
Phenylpropanolamine—ADRA2A—brain—attention deficit hyperactivity disorder	0.000313	0.0064	CbGeAlD
Phenylpropanolamine—Phentermine—SLC6A3—attention deficit hyperactivity disorder	0.000296	0.0476	CrCbGaD
Phenylpropanolamine—Dextroamphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000282	0.0454	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—SLC6A3—attention deficit hyperactivity disorder	0.00028	0.0451	CrCbGaD
Phenylpropanolamine—Phenelzine—MAOA—attention deficit hyperactivity disorder	0.00028	0.045	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—ADRA2A—attention deficit hyperactivity disorder	0.000275	0.0443	CrCbGaD
Phenylpropanolamine—Methamphetamine—MAOA—attention deficit hyperactivity disorder	0.000244	0.0394	CrCbGaD
Phenylpropanolamine—Amphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000227	0.0366	CrCbGaD
Phenylpropanolamine—Phentermine—SLC6A4—attention deficit hyperactivity disorder	0.000221	0.0356	CrCbGaD
Phenylpropanolamine—Methamphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000211	0.0339	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—SLC6A4—attention deficit hyperactivity disorder	0.00021	0.0338	CrCbGaD
Phenylpropanolamine—Methamphetamine—ADRA2A—attention deficit hyperactivity disorder	0.000207	0.0333	CrCbGaD
Phenylpropanolamine—Amphetamine—SLC6A4—attention deficit hyperactivity disorder	0.00017	0.0274	CrCbGaD
Phenylpropanolamine—Amphetamine—DRD2—attention deficit hyperactivity disorder	0.000169	0.0272	CrCbGaD
Phenylpropanolamine—Methamphetamine—SLC6A4—attention deficit hyperactivity disorder	0.000158	0.0254	CrCbGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	6.08e-05	0.000455	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	6.03e-05	0.000452	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	6e-05	0.00045	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	5.97e-05	0.000447	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	5.91e-05	0.000443	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	5.9e-05	0.000442	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	5.89e-05	0.000441	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	5.85e-05	0.000438	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	5.84e-05	0.000438	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	5.83e-05	0.000437	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	5.83e-05	0.000436	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	5.81e-05	0.000435	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	5.76e-05	0.000431	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	5.74e-05	0.00043	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	5.72e-05	0.000429	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	5.71e-05	0.000427	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	5.68e-05	0.000426	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	5.65e-05	0.000423	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	5.58e-05	0.000418	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	5.55e-05	0.000416	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	5.53e-05	0.000414	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	5.48e-05	0.000411	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	5.48e-05	0.000411	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	5.43e-05	0.000407	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	5.43e-05	0.000407	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	5.42e-05	0.000406	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	5.41e-05	0.000406	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	5.4e-05	0.000404	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	5.36e-05	0.000402	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	5.36e-05	0.000402	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	5.31e-05	0.000398	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	5.31e-05	0.000398	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	5.31e-05	0.000397	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.23e-05	0.000392	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	5.2e-05	0.000389	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	5.13e-05	0.000385	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	5.11e-05	0.000383	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	5.08e-05	0.00038	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	5.04e-05	0.000378	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	5e-05	0.000374	CbGpPWpGaD
Phenylpropanolamine—MAOA—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	4.89e-05	0.000366	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	4.83e-05	0.000362	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	4.79e-05	0.000359	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	4.79e-05	0.000359	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.78e-05	0.000358	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	4.75e-05	0.000356	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	4.73e-05	0.000355	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	4.72e-05	0.000354	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	4.72e-05	0.000353	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.7e-05	0.000352	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.67e-05	0.00035	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.6e-05	0.000344	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	4.57e-05	0.000342	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.51e-05	0.000338	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	4.49e-05	0.000337	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	4.49e-05	0.000336	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	4.44e-05	0.000332	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	4.44e-05	0.000332	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	4.4e-05	0.00033	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	4.39e-05	0.000329	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	4.38e-05	0.000328	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.31e-05	0.000323	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	4.3e-05	0.000322	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	4.25e-05	0.000318	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.15e-05	0.000311	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	4.13e-05	0.00031	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	4.12e-05	0.000309	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	4.12e-05	0.000309	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.1e-05	0.000307	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	4.08e-05	0.000305	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.06e-05	0.000304	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	3.99e-05	0.000299	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.98e-05	0.000298	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.97e-05	0.000297	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	3.95e-05	0.000296	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.94e-05	0.000295	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	3.89e-05	0.000291	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	3.87e-05	0.00029	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	3.86e-05	0.000289	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	3.84e-05	0.000288	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	3.84e-05	0.000287	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	3.8e-05	0.000285	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.73e-05	0.000279	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.68e-05	0.000276	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.65e-05	0.000273	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.6e-05	0.00027	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	3.59e-05	0.000269	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.58e-05	0.000268	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.58e-05	0.000268	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.56e-05	0.000267	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.55e-05	0.000266	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.55e-05	0.000266	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	3.53e-05	0.000265	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.5e-05	0.000262	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.49e-05	0.000262	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.49e-05	0.000261	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.47e-05	0.00026	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.45e-05	0.000258	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.42e-05	0.000257	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.3e-05	0.000247	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.28e-05	0.000246	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.22e-05	0.000242	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.22e-05	0.000242	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.22e-05	0.000241	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.21e-05	0.000241	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.2e-05	0.00024	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.19e-05	0.000239	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.17e-05	0.000237	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.15e-05	0.000236	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.14e-05	0.000235	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.14e-05	0.000235	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.13e-05	0.000235	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.13e-05	0.000234	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.12e-05	0.000234	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.1e-05	0.000232	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.08e-05	0.000231	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.07e-05	0.00023	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.07e-05	0.00023	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.05e-05	0.000228	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.03e-05	0.000227	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.02e-05	0.000226	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.01e-05	0.000226	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.99e-05	0.000224	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	2.98e-05	0.000223	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—TPH2—attention deficit hyperactivity disorder	2.98e-05	0.000223	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.98e-05	0.000223	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—DPYD—attention deficit hyperactivity disorder	2.93e-05	0.000219	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.93e-05	0.000219	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.92e-05	0.000218	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.9e-05	0.000217	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	2.89e-05	0.000217	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.89e-05	0.000216	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.88e-05	0.000216	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	2.87e-05	0.000215	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.85e-05	0.000213	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.84e-05	0.000212	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.82e-05	0.000212	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.81e-05	0.000211	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	2.8e-05	0.00021	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.79e-05	0.000209	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	2.77e-05	0.000207	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.75e-05	0.000206	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.72e-05	0.000204	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	2.69e-05	0.000201	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.67e-05	0.0002	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	2.67e-05	0.0002	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.62e-05	0.000196	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.6e-05	0.000195	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.59e-05	0.000194	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.58e-05	0.000193	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.56e-05	0.000192	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.54e-05	0.00019	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.54e-05	0.00019	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.51e-05	0.000188	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.49e-05	0.000187	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.48e-05	0.000186	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.42e-05	0.000181	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.42e-05	0.000181	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.42e-05	0.000181	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.41e-05	0.00018	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.4e-05	0.00018	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.38e-05	0.000178	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.36e-05	0.000177	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.35e-05	0.000176	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.34e-05	0.000175	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.33e-05	0.000175	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.31e-05	0.000173	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.31e-05	0.000173	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.28e-05	0.000171	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.26e-05	0.00017	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.25e-05	0.000169	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.25e-05	0.000168	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.18e-05	0.000163	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.18e-05	0.000163	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.17e-05	0.000163	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.13e-05	0.000159	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.12e-05	0.000159	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.12e-05	0.000158	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.12e-05	0.000158	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.04e-05	0.000153	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.02e-05	0.000151	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	1.99e-05	0.000149	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.99e-05	0.000149	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.98e-05	0.000148	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.97e-05	0.000148	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	1.96e-05	0.000147	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.9e-05	0.000143	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.9e-05	0.000142	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.87e-05	0.00014	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.86e-05	0.000139	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.85e-05	0.000139	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.84e-05	0.000138	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.82e-05	0.000136	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—COMT—attention deficit hyperactivity disorder	1.8e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.8e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.77e-05	0.000132	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.76e-05	0.000132	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.73e-05	0.00013	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.72e-05	0.000129	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.71e-05	0.000128	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.68e-05	0.000126	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.68e-05	0.000125	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.66e-05	0.000125	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.65e-05	0.000123	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.64e-05	0.000123	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.64e-05	0.000123	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.63e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.59e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.59e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.55e-05	0.000116	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.54e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.52e-05	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.51e-05	0.000113	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.49e-05	0.000111	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.43e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.43e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.39e-05	0.000104	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.38e-05	0.000103	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.36e-05	0.000102	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.35e-05	0.000101	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.33e-05	9.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.29e-05	9.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	1.27e-05	9.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.25e-05	9.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.25e-05	9.36e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.21e-05	9.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	1.2e-05	9.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	1.2e-05	8.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.16e-05	8.72e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.1e-05	8.22e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	1.1e-05	8.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.08e-05	8.13e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	1.08e-05	8.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.06e-05	7.95e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1e-05	7.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.78e-06	6.57e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	8.78e-06	6.57e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.35e-06	6.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.15e-06	6.11e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—EP300—attention deficit hyperactivity disorder	7.73e-06	5.79e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	6.65e-06	4.98e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	6.6e-06	4.95e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	6.4e-06	4.8e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.39e-06	4.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.75e-06	4.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.62e-06	4.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	5.17e-06	3.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.65e-06	3.48e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.32e-06	3.24e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	2.85e-06	2.14e-05	CbGpPWpGaD
